Xconomy: alirocumab News, Articles and Opinions

“alirocumab” Archives

Entry	Author	Date	Location
New PCSK9 Cholesterol Drug Faces Tough Foe. (Hint: Not Cholesterol.)	Alex Lash	08/26/19	National
MedCo Touts New Data for Long-Lasting Heart Drug as Reckoning Looms	Ben Fidler	05/20/19	New York
Matching Amgen, Regeneron to Cut List Price of Heart Drug by 60%	Ben Fidler	02/11/19	New York
15 For ’19: Key Clinical Data to Watch For Next Year (Part 2)	Ben Fidler	12/18/18	National
Amgen Slashes Cholesterol Drug Price 60% to Match Rival Regeneron	Frank Vinluan	10/24/18	National
Bio Roundup: CRISPR Ruling, “America’s Nobels,” IPOs & More	Frank Vinluan	09/14/18	National
Trump Pledges Lower Drug Prices, But Blueprint Is Short on Details	Ben Fidler	05/11/18	National
Bio Roundup: IDO Fallout, Express Scripts Dumps Amgen, Isaly Out & More	Ben Fidler	05/04/18	National
Express Scripts Picks Regeneron Over Amgen, Cuts Heart Drug Price	Ben Fidler	05/01/18	New York
Bio Roundup: DIY Biohacking, PCSK9 Data, Solid Setback & More	Frank Vinluan	03/16/18	National
Regeneron to Slash Price of Cholesterol Drug After Showing It Saved Lives	Ben Fidler	03/10/18	New York
Bio Roundup: Trump Health, Cholesterol Wars, 23andMe OK & More	Alex Lash	03/09/18	National
Esperion Touts Low Cholesterol Drug Price, But Not All Data are Ready	Alex Lash	03/07/18	Detroit Ann Arbor
Medicines Co. Sells Infectious Disease Drugs, Focusing on PCSK9	David Holley	11/29/17	New York
70% Repatha Cut? Amgen Counters With Own Study To Justify Price	Alex Lash	08/23/17	National
Amgen’s Heart Data Don’t Impress Drug-Price Evaluation Group	Alex Lash	06/13/17	San Francisco
The Medicines Co., Alnylam Take Plunge, Outline Big Test For Heart Drug	Ben Fidler	04/26/17	New York
FDA OKs Eczema Injection; Owners Regeneron, Sanofi Set $37K Price	Alex Lash	03/28/17	New York
With New Data, Amgen Promises Refund If Cholesterol Drug Doesn’t Work	Ben Fidler	03/17/17	San Francisco
Cashing in On Duchenne Approval, Sarepta Sells Voucher to Gilead For $125M	Ben Fidler	02/21/17	Boston
Bio Roundup: Travel Ban Block, Gilead Shock, Dean Kamen Talk & More	Alex Lash	02/10/17	National
14 For ’17: Key Clinical Data to Watch For Next Year (Part 1)	Ben Fidler	12/21/16	National
Regeneron: It’s Still Wait Until 2017 For Big Heart Drug Study	Ben Fidler	11/17/16	New York
With New Data, Medicines Co. Takes Long-Lasting Heart Drug to Phase 3	Ben Fidler	11/15/16	New York
In Cholesterol Drug Price Fight, Real Message Is “Wait Til Next Year”	Alex Lash	08/18/16	National
Intercept’s Liver Drug Wins FDA Approval To Treat Rare Disease	Alex Lash	05/28/16	New York
East Coast Biotech Roundup: NY Bio, Gender Gap, Zafgen, PureTech & More	Ben Fidler	05/12/16	Boston
Making the Price Right: Ideas To Change Drug Costs Gain Momentum	Alex Lash	04/05/16	National
East Coast Bio Roundup: PCSK9 Battle, NYU Startups, Blueprint & More	Ben Fidler	03/17/16	Boston
Amgen Bests Sanofi-Regeneron In PCSK9 Patent Case, Losers Vow Appeal	Alex Lash	03/16/16	New York
Page 1 of 2	next page »

Underwriters and Partners

Xpertise: Watch + Learn

Xconomy Insight · Special Report
How to Jump 5 Unforeseen Hurdles to Biotech Success – Startup Sourcebook
Insights, wisdom, and inspiration on what it takes

Sponsored · Whitepaper
Monitoring Solutions for Pharma-CRO/CMO Partnerships to Maintain Quality & Timelines
Implementing electronic solutions for risk mitigation
XiltriX

Xconomy Insight · Webinar
The New Era of Emerging Therapies Webinar Series
Potential cures and treatments for diseases are on the horizon for a growing number of patients, thanks to recent breakthroughs in CRISPR gene-editing technologies and in cell and gene therapy.